You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
瑞康醫藥(002589.SZ)業績快報:2019年業績由盈轉虧至10.21億元
格隆匯 02-21 08:39

格隆匯2月21日丨瑞康醫藥(002589.SZ)披露2019年度業績快報,報告期內,公司實現營業收入353.33億元,同比增長4.17%;營業利潤1.97億元,同比減少90.04%;利潤總額1.70億元,同比減少91.32%;歸屬於上市公司股東的淨利潤為虧損10.21億元,上年同期為盈利7.79億元;利潤減少主要原因為:

1、近年來,公司抓住政策和市場機遇,通過一系列的投資併購,加速打造全國性、綜合性的醫療器械直銷網絡,完善和拓展公司產業佈局。由於公司外延收購的近兩百家公司具有輕資產屬性,在合併時形成了較大金額的商譽。受國內宏觀經濟下行壓力影響,結合行業政策變化及子公司實際經營情況等因素,公司根據證監會《會計監管風險提示第8號----商譽減值》及相關會計政策規定,對報告期內所有子公司的經營情況進行了全面估計。2019年公司多數子公司實現盈利,但業績沒有完全達到預期,基於謹慎性原則,2019年度預計對90餘個資產組計提商譽減值準備金額約為22.4億元;最終商譽減值準備計提將由公司聘請的具備證券期貨從業資格的評估機構及審計機構進行評估和審計後確定;

2、因衍生金融負債變動原因產生公允價值變動損益約5.5億元,對應遞延所得税費用影響1.38億元;

3、公司業務全國化之後,加大省級平台建設,在信息化投入、人員、倉庫、市場推廣等銷售、管理兩項費用支出階段性上升;

4、為加速公司應收賬款回收和週轉,本期加大供應鏈金融和資產證券化等融資,導致財務費用有所增加。

上述資產減值損失不會對公司的現金流產生任何影響,亦不會影響公司現有主業及後續年度的正常經營。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account